CJMB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CJMB is not a good buy right now for a beginner with a long-term focus and $50,000-$100,000 to invest. The stock lacks strong bullish catalysts, has weak recent financial performance, no supportive analyst or news momentum, and no proprietary buy signal. Even though the technicals show slight short-term stabilization, the overall setup does not justify an immediate buy for an impatient long-term investor.
The stock closed at 1.05, near its pivot level of 1.047, which suggests short-term indecision. MACD histogram is slightly positive at 0.0282 and expanding, which is mildly bullish, but RSI_6 at 60.1 is only neutral-to-slightly bullish and not a strong momentum signal. Moving averages are converging, indicating a lack of clear trend direction. Resistance is nearby at 1.185 and 1.271, while support sits at 0.908 and 0.822. Overall, the chart shows a weak recovery attempt rather than a confirmed uptrend.
No news in the recent week means there are no clear event-driven positive catalysts. The stock is near pivot support, and MACD is mildly improving, which offers only a limited technical tailwind.
Revenue in 2025/Q4 fell 14.14% year over year, gross margin also declined, and net income remained deeply negative at -2.59M despite improving versus last year. There was no recent news, no valuation support, no significant hedge fund or insider buying trend, and no AI Stock Picker or SwingMax signal. Congress trading data is also absent. Sentiment is therefore weak.
In 2025/Q4, revenue dropped to 1,160,574, down 14.14% YoY, showing declining top-line momentum. Net income was -2,593,039, which is still negative, although the YoY comparison improved. EPS was -0.55, also improved year over year but still unprofitable. Gross margin fell to 30.53%, down 1.52% YoY. The latest quarter shows some loss improvement, but overall fundamentals remain weak due to shrinking revenue and ongoing losses.
No recent analyst rating or price target change data was provided, so there is no evidence of improving Wall Street sentiment. Based on the available information, the Wall Street view appears neutral to cautious: there are no analyst upgrades, no target increases, no news-driven optimism, and no visible institutional accumulation. Pros: slight technical stabilization and some year-over-year improvement in losses. Cons: declining revenue, weak margins, persistent unprofitability, and no supportive catalyst or proprietary signal.
